A Study of the Safety and Effectiveness of Levofloxacin Compared to Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Skin Infections
Information source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Skin Diseases, Bacterial
Intervention: levofloxacin (Drug)
Phase: Phase 3
Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Official(s) and/or principal investigator(s):
Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The purpose of this study is to compare the safety and effectiveness of levofloxacin (an
antibiotic) with ticarcillin/clavulanate alone or followed by amoxicillin/clavulanate in the
treatment of complicated skin infections.
Official title: A Multicenter, Randomized, Open-Label Study to Compare the Safety and Efficacy of i.v. And/Or Oral Levofloxacin With That of Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Bacterial Skin and Skin Structure Infections
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Clinical response rates at post-therapy, categorized as cured, improved, or failed.
Secondary outcome: Rate of elimination of disease-causing bacteria post-study, by patient, and by bacteria type; Clinical relapse and new infection rates based upon signs and symptoms at post-study; Microbiologic relapse rates
Levofloxacin is an antibiotic that has been evaluated in clinical trials for use in the
treatment of many types of infections including respiratory tract, urinary tract, and
uncomplicated skin infections. Levofloxacin may be taken by mouth or administered slowly
through a vein and has been shown to be safe and effective when administered once daily.
This multicenter, open-label study will evaluate the safety and effectiveness of a single
daily oral or intravenous dose of levofloxacin compared to multiple daily intravenous doses
with another antibiotic, ticarcillin/clavulanate given alone or followed by oral
amoxicillin/clavulanate, in the treatment of bacterial skin infections. Patients will
receive 750 mg of levofloxacin by mouth or intravenously for 7 - 14 days, or 3. 1 grams of
ticarcillin/clavulanate intravenously for 7 - 14 days. Patients receiving levofloxacin
intravenously may be switched to receive levofloxacin by mouth; patients receiving
ticarcillin/clavulanate intravenously may be switched to 875 mg of amoxicillin/clavulanate
given by mouth, twice daily, if significant improvement is noted. Patients are assessed
after 3 - 4 days of treatment; treatment is discontinued if no significant improvement is
noted. Patients showing signs of improvement continue in the study, with assessments 2 - 5
days (post-therapy visit) and 3 - 4 weeks (post-study visit) after completion of the study
drug. The primary measure of effectiveness is the clinical response rate assessed 2 - 5 days
after the last dose of antibiotic treatment, categorizing the response as cured, improved,
or failed. Laboratory tests for the presence of bacteria are performed throughout the study.
Safety evaluations (incidence of adverse events, physical examinations, laboratory tests)
are performed throughout the study. The study hypothesis is that a single daily dose of
levofloxacin is at least as effective as multiple daily doses of ticarcillin/clavulanate
alone or followed by amoxicillin/clavulanate in the treatment of skin infections, and that
it is well tolerated. Levofloxacin 750 mg intravenously or by mouth, once daily for 7 - 14
days, or ticarcillin/clavulanate 3. 1 grams intravenously every 4 - 6 hours, may be switched
to amoxicillin/clavulanate 875 mg by mouth, twice daily, total duration 7 - 14 days.
Minimum age: 18 Years.
Maximum age: N/A.
- Diagnosis of bacterial skin and skin structure infection with a complicating factor,
(including a pre-existing skin lesion, or a condition affecting the way the drug gets
to the infected area of the body, the body's disease defense (immune) system, or the
ability of tissues to heal properly)
- have at least 2 of the following signs and symptoms of skin infection: pain, redness,
swelling, hardness, pus formation
- have an infection of one of the following types: wound infections (crush, puncture,
cut, gunshot, surgery, bite), infected skin ulcers, or infections in patients with
decreased immune system function (HIV infections, diabetes, etc)
- able to provide a sample of tissue from the affected area of the skin
- Patients with multiple infected ulcers at separate locations on body
- requiring immediate surgery at the infection site
- having low blood pressure, decreased urination, decreased kidney function, seizure
disorder, unstable mental disorder, low white blood cell count, bone infection,
shock, or are HIV positive
- having an infection from a bacteria known to be resistant to any of the study drugs
- having a previous allergic or serious reaction to any of the study drugs
Locations and Contacts
A study of the safety and effectiveness of levofloxacin compared to ticarcillin/clavulanate alone or followed by amoxicillin/clavulanate in the treatment of skin infections
Starting date: January 1997
Last updated: June 8, 2011